Dyne Therapeutics, Inc.
DYN
$20.09
$0.100.50%
NASDAQ
| 09/30/2025 | 06/30/2025 | 03/31/2025 | 12/31/2024 | 09/30/2024 | |
|---|---|---|---|---|---|
| Net Income | -11.24% | -70.28% | -75.72% | -34.37% | -61.31% |
| Total Depreciation and Amortization | 19.41% | 26.07% | 30.05% | 12.78% | 1.62% |
| Total Amortization of Deferred Charges | -- | -- | -- | -- | -- |
| Total Other Non-Cash Items | 37.96% | 79.02% | -35.73% | 72.55% | 68.46% |
| Change in Net Operating Assets | -58.61% | 32.95% | 89.03% | -119.92% | 215.09% |
| Cash from Operations | -21.64% | -72.60% | -34.83% | -140.92% | -47.48% |
| Capital Expenditure | -7,483.00% | 93.00% | -413.61% | -1,210.98% | -51.50% |
| Sale of Property, Plant, and Equipment | -- | -- | -- | -- | -- |
| Cash Acquisitions | -- | -- | -- | -- | -- |
| Divestitures | -- | -- | -- | -- | -- |
| Other Investing Activities | 1.93% | -43.20% | 101.36% | -156.83% | -247.44% |
| Cash from Investing | -95.67% | -39.38% | 100.81% | -161.12% | -251.34% |
| Total Debt Issued | -- | -- | -- | -- | -- |
| Total Debt Repaid | -- | -- | -- | -- | -- |
| Issuance of Common Stock | 1,109.82% | -99.48% | -65.41% | 2,373.47% | 3,866.74% |
| Repurchase of Common Stock | -- | -- | -- | -- | -- |
| Issuance of Preferred Stock | -- | -- | -- | -- | -- |
| Repurchase of Preferred Stock | -- | -- | -- | -- | -- |
| Total Dividends Paid | -- | -- | -- | -- | -- |
| Other Financing Activities | -- | -- | -- | -- | -- |
| Cash from Financing | 1,106.77% | -73.47% | -65.41% | 2,373.47% | 3,866.74% |
| Foreign Exchange rate Adjustments | -- | -- | -- | -- | -- |
| Miscellaneous Cash Flow Adjustments | -- | -- | -- | -- | -- |
| Net Change in Cash | 216.52% | -96.18% | -75.46% | -1,016.35% | -103.67% |